Combination treatments for relapsed high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have neuroblastoma that has come back (relapsed) after high-risk treatment.
- The tumor must be visible on a CT or MIBG scan (not just in the bone marrow).
- Your child must be at least 1 year old and have a life expectancy of at least 12 weeks.
- Your child's blood counts, kidney function, and liver function must meet certain levels (your doctor will check these).
- Your child must not have had more than one relapse (for the first treatment option) or must have had more than one relapse (for the second treatment option).
- Your child must not have had severe allergic reactions to certain prior treatments like anti-GD2 antibodies or bevacizumab, depending on the treatment group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
Hear when a new Relapsed Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.